Prostate Adenocarcinoma
Prostate Adenocarcinoma is the most common subtype of prostate cancer and accounts for the vast majority of all prostate cancer cases. At Alfa Cytology, our team of specialists is dedicated to addressing the challenges of denervation-resistant prostate adenocarcinoma Leveraging our in-depth expertise and state-of-the-art technologies, we provide you with premier solutions tailored to your needs.
Introduction to Prostate Adenocarcinoma
Prostate adenocarcinoma is the most common type of cancer affecting the prostate gland in men. This malignant tumor originates in the glandular epithelial cells of the prostate, which are responsible for the production of prostate fluid, a component of semen. Prostate adenocarcinoma is characterized by abnormal cell growth, which leads to the development of tumors that can invade nearby tissues and metastasize to distant sites.
Fig. 1 Histology of DAC. Black arrows indicate ductal cancer glands. Red arrow indicates extra-prostatic extension. Scale bar 500 µm. (Ranasinha, N., et al. 2021)
Adenocarcinomas are categorized based on their degree of glandular development into well, moderately, or poorly differentiated types. Well-differentiated adenocarcinomas of the prostate are characterized by the presence of distinct and well-formed glandular structures, while poorly-differentiated forms are marked by solid cell clusters or sheets with little to no glandular structure.
Our Services
Currently, therapeutic development for prostate adenocarcinoma is moving towards diversification and precision. At Alfa Cytology, we offer an integrated therapeutic development platform for prostate adenocarcinoma, dedicated to providing effective solutions for this prevalent cancer type.
One-Stop Solutions for Prostate Adenocarcinoma
Alfa Cytology provides a variety of well-established development platforms, specializing in multiple key targets, to facilitate the development of a broad spectrum of drug types.
Tumor Model Development Services
We provide a diverse range of preclinical models to accelerate your drug development process.
| Name | Description |
| Conventional Cell Lines | |
| LNCaP | Androgen-sensitive cell line with a classic AR mutation, derived from lymph node metastasis. |
| PC-3 | Highly aggressive, androgen-insensitive cell line derived from a bone metastasis. |
| 22Rv1 | Cell line expressing AR splice variants (e.g., AR-V7), model for castration-resistant progression. |
| DU 145 | Androgen-insensitive cell line derived from a brain metastasis. |
| VCaP | Androgen-sensitive cell line derived from a vertebral metastasis and harbors the TMPRSS2-ERG fusion. |
| Cell Line-Derived Xenograft (CDX) Models | |
| LNCaP/VCaP/22Rv1 CDX | Immunodeficient mouse models of androgen-sensitive tumor growth. |
| PC-3/DU 145 CDX | Immunodeficient mouse models of androgen-independent, aggressive tumor growth. |
Case Study
Orthotopic LNCaP Prostatic Adenocarcinoma Model
- Model Information
Cell Line: LNCaP cell lines
Age: 5-6 weeks
Weight: 18-22 g
Species: SCID mice
Sex: Male
Fig. 2 Establishment of LNCaP-derived prostatic adenocarcinoma model
This model is established via direct microinjection of LNCaP human prostate cancer cells into the ventral prostate lobe of anesthetized SCID mice. Utilizing a refined surgical approach, a lower abdominal incision is made to expose the prostate, allowing for precise, intraparenchymal delivery of tumor cells.
- Results
Disease progression and therapeutic response are longitudinally assessed by monitoring survival, with data analyzed via Kaplan-Meier curves (Fig. 3). At the study endpoint, the primary prostate tumor and associated tissues are harvested for comprehensive histopathological evaluation, enabling detailed analysis of tumor morphology and local invasion (Fig. 4).
Fig. 3 Survival analysis of mice in the LNCaP-derived prostatic adenocarcinoma model
Fig. 4 Representative H&E staining of tumor tissues from LNCaP-derived prostatic adenocarcinoma model
If you are looking for therapy development services for prostate adenocarcinoma, our expert team can provide comprehensive support. By partnering with Alfa Cytology, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Ranasinha, N., et al. Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI compass. 2021, 2(1): 13-23.
For research use only.